Cargando…
Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593794/ https://www.ncbi.nlm.nih.gov/pubmed/37872229 http://dx.doi.org/10.1038/s41467-023-42562-2 |
| _version_ | 1785124508127985664 |
|---|---|
| author | Al-Sawaf, Othman Zhang, Can Jin, Hyun Yong Robrecht, Sandra Choi, Yoonha Balasubramanian, Sandhya Kotak, Alex Chang, Yi Meng Fink, Anna Maria Tausch, Eugen Schneider, Christof Ritgen, Matthias Kreuzer, Karl-Anton Chyla, Brenda Paulson, Joseph N. Pallasch, Christian P. Frenzel, Lukas P. Peifer, Martin Eichhorst, Barbara Stilgenbauer, Stephan Jiang, Yanwen Hallek, Michael Fischer, Kirsten |
| author_facet | Al-Sawaf, Othman Zhang, Can Jin, Hyun Yong Robrecht, Sandra Choi, Yoonha Balasubramanian, Sandhya Kotak, Alex Chang, Yi Meng Fink, Anna Maria Tausch, Eugen Schneider, Christof Ritgen, Matthias Kreuzer, Karl-Anton Chyla, Brenda Paulson, Joseph N. Pallasch, Christian P. Frenzel, Lukas P. Peifer, Martin Eichhorst, Barbara Stilgenbauer, Stephan Jiang, Yanwen Hallek, Michael Fischer, Kirsten |
| author_sort | Al-Sawaf, Othman |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10593794 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-105937942023-10-25 Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia Al-Sawaf, Othman Zhang, Can Jin, Hyun Yong Robrecht, Sandra Choi, Yoonha Balasubramanian, Sandhya Kotak, Alex Chang, Yi Meng Fink, Anna Maria Tausch, Eugen Schneider, Christof Ritgen, Matthias Kreuzer, Karl-Anton Chyla, Brenda Paulson, Joseph N. Pallasch, Christian P. Frenzel, Lukas P. Peifer, Martin Eichhorst, Barbara Stilgenbauer, Stephan Jiang, Yanwen Hallek, Michael Fischer, Kirsten Nat Commun Author Correction Nature Publishing Group UK 2023-10-23 /pmc/articles/PMC10593794/ /pubmed/37872229 http://dx.doi.org/10.1038/s41467-023-42562-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Author Correction Al-Sawaf, Othman Zhang, Can Jin, Hyun Yong Robrecht, Sandra Choi, Yoonha Balasubramanian, Sandhya Kotak, Alex Chang, Yi Meng Fink, Anna Maria Tausch, Eugen Schneider, Christof Ritgen, Matthias Kreuzer, Karl-Anton Chyla, Brenda Paulson, Joseph N. Pallasch, Christian P. Frenzel, Lukas P. Peifer, Martin Eichhorst, Barbara Stilgenbauer, Stephan Jiang, Yanwen Hallek, Michael Fischer, Kirsten Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia |
| title | Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia |
| title_full | Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia |
| title_fullStr | Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia |
| title_full_unstemmed | Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia |
| title_short | Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia |
| title_sort | author correction: transcriptomic profiles and 5-year results from the randomized cll14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia |
| topic | Author Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10593794/ https://www.ncbi.nlm.nih.gov/pubmed/37872229 http://dx.doi.org/10.1038/s41467-023-42562-2 |
| work_keys_str_mv | AT alsawafothman authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT zhangcan authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT jinhyunyong authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT robrechtsandra authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT choiyoonha authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT balasubramaniansandhya authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT kotakalex authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT changyimeng authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT finkannamaria authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT tauscheugen authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT schneiderchristof authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT ritgenmatthias authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT kreuzerkarlanton authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT chylabrenda authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT paulsonjosephn authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT pallaschchristianp authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT frenzellukasp authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT peifermartin authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT eichhorstbarbara authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT stilgenbauerstephan authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT jiangyanwen authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT hallekmichael authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia AT fischerkirsten authorcorrectiontranscriptomicprofilesand5yearresultsfromtherandomizedcll14studyofvenetoclaxplusobinutuzumabversuschlorambucilplusobinutuzumabinchroniclymphocyticleukemia |